The United Kingdom and the United States have signed a major trade agreement that will ensure zero levies on British drug products going into the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to raise expenditure on medicines through the NHS. This pledge ensures that duties on these vital products will remain at nothing for a timeframe of 36 months.
This agreement comes after earlier threats to hike duties on patented pharmaceutical products, with increases mentioned as high as one hundred percent.
"This agreement between the United Kingdom strengthens the international landscape for innovative medicines and brings much-needed equity to U.S.–U.K. drug exports," a statement declared.
Trade Significance
Pharmaceuticals are one of the the United Kingdom's biggest exports to the US, which is by far the biggest market for major British pharmaceutical firms.
Trade data reveal that in the year prior to last September, the UK sold drugs totaling £11.1bn to the US. This amount represented 17.4% of total UK exports in that span.
"This agreement secures work, increases funding and paves the way for the UK to become a global hub for biotech and pharma," a minister commented.
Key British Pledges
The agreement includes several specific pledges from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a goal to increase overall public funding on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum drug companies must refund to the NHS to stay within budget will be limited at 15%. Last year, repayments exceeded 20%.
Broader Context
The pact follows a protracted tension between the sector and the ministers over medicine costs and NHS adoption.
The disagreement were heightened by claims that US patients were paying several times more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been paused or scrapped, while substantial expansions have been pledged toward American operations.
One official acknowledged that the NHS needed to spend more on medicines, noting that its expenditure on drugs had shrunk as a percentage of its resources over the last ten years.
